CLINICAL DATA
The ULTIMA Trial
SEATTLE II Trial
OPTALYSE PE
Nykamp-Laurich
CLINICAL DATA
The ULTIMA Trial
SEATTLE II Trial
OPTALYSE PE
Nykamp-Laurich
Vascular Surgery / Venous Thromboembolism Portal / Pulmonary Embolism / Clinical Data / SEATTLE II Trial

 

SEATTLE II Trial
EKOS Endovascular System PE Clinical Studies

 

 

A Prospective, Single-Arm, Multicentre Trial of Ultrasound-Facilitated, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism
G. Piazza MD, MS et al, JACC Cardiovasc Interv. 2015 Aug 24; 8(10): 1382-92

SEATTLE II Trial

 

Key Results

25% decrease in RV/LV ratio over 48 hours.
Minimised risk of intracranial haemorrhage.
Rapidly relieved pulmonary artery obstruction.
Reduced pulmonary hypertension.

 

25% Decrease in RV/LV Ratio
Over 48 Hours

25% Decrease in RV/LV Ratio Over 48 Hours
Minimised Risk of
Intracranial Haemorrhage

Minimised Risk of Intracranial Haemorrhage
Rapidly Relieved Pulmonary
Artery Obstruction

Rapidly Relieved Pulmonary Artery Obstruction
Minimised Risk of
Intracranial Haemorrhage

Reduced Pulmonary Hypertension


Conclusions

Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute PE improves RV function and decreases pulmonary hypertension and angiographic obstruction. By minimising the risk of intracranial bleed, it represents a potential “game-changer” in the treatment of high-risk PE patients.

 

 

Top